Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25884472 | 0.88 | ALOX15 (0.50) | ALOX15KAT2BPDE9A | |
| SCHEMBL23082859 | 0.81 | ALOX15 (0.45) | ALOX15PDE9A | |
| SCHEMBL19203134 | 0.81 | ALOX15 (0.38) | HSP90AA1HSP90AB1ALOX15CYP11B1CYP11B2 | |
| SCHEMBL22789033 | 0.79 | CYP11B1 (0.36) | HSP90AA1HSP90AB1ALOX15CYP11B1CYP11B2 | |
| SCHEMBL13843728 | 0.77 | PDE9A (0.33) | HSP90AA1HSP90AB1ALOX15NLRP3PDE9A | |
| SCHEMBL25463364 | 0.77 | PDE9A (0.33) | ALOX15PDE9A | |
| SCHEMBL26830062 | 0.75 | NTRK1 (0.33) | HSP90AA1HSP90AB1ALOX15CYP11B1CYP11B2 | |
| SCHEMBL23083134 | 0.75 | MAP3K12 (0.37) | ALOX15PDE9A | |
| SCHEMBL4036020 | 0.75 | ALDH1A1 (0.37) | ALOX15PDE9A | |
| SCHEMBL23323903 | 0.75 | ALOX15 (0.44) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020055672-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-03-19 | — | — | WO | disclosed |